TECH · Bio-Techne Corporation
$53.132026-05-17Sector: Healthcare; Industry: Biotechnology; Sub-Industry: Life Sciences Tools & Services
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Base · active
$12
-77.1% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($13 · $12) Analysts Range ($62 · $79) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2022.Q2 | $931MM | — | 32.0% | 2.4% | $291MM | −$199MM | $92MM | 8.3% | — | 15.2% | $1.9B | $0.89 | — |
| 2023.Q2 | $1.1B | 18.7% | 33.7% | 17.7% | $307MM | −$118MM | $190MM | 10.2% | — | 15.3% | $2.1B | $1.73 | — |
| 2024.Q2 | $1.1B | 2.8% | 33.1% | 10.9% | $335MM | −$190MM | $145MM | 10.1% | — | 14.5% | $2.5B | $1.82 | — |
| 2025.Q2 | $1.2B | 2.0% | 22.4% | 14.9% | $221MM | $179MM | $400MM | 11.4% | — | 8.8% | $2.5B | $1.07 | — |
| 2026.Q2 | $1.2B | 4.9% | 12.1% | 29.0% | $104MM | $61MM | $166MM | 11.0% | — | 4.3% | $2.4B | $0.52 | 56.7 |
| italics below = DCF projection · 10yr Rev CAGR: 7.7% |
| 2027.Q2 | $1.3B | +3.9% | 15.2% | 28.1% | $138MM | −$95MM | $43MM | 10.5% | $39MM | 5.7% | $2.5B | $0.56 | 94.9 |
| 2028.Q2 | $1.4B | +8.3% | 16.1% | 27.2% | $160MM | −$216MM | −$56MM | 10.3% | −$46MM | 6.2% | $2.7B | $0.69 | 77.0 |
| 2029.Q2 | $1.5B | +8.2% | 17.0% | 26.3% | $186MM | −$237MM | −$51MM | 10.1% | −$38MM | 6.6% | $2.9B | $0.84 | 63.3 |
| 2030.Q2 | $1.6B | +9.0% | 17.9% | 25.4% | $216MM | −$286MM | −$71MM | 9.9% | −$48MM | 7.0% | $3.2B | $1.01 | 52.6 |
| 2031.Q2 | $1.8B | +11.8% | 19.7% | 24.5% | $268MM | −$418MM | −$150MM | 9.7% | −$93MM | 7.8% | $3.6B | $1.36 | 39.1 |
|
| Term. Yr+ | $2.7B | 4.1% | 19.7% | 20.0% | $417MM | −$199MM | $218MM | 8.6% | $1.9B | 8.6% | — | — | — |
Active scenario IV: $12 (-77.1% vs market)